1. Australia Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
ReNerve Limited

ReNerve Limited

RNV.AX
ReNerve LimitedAU flagAustralian Securities Exchange
0.08
AUD
+0.00
- -
14.56MMarket Cap
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
Revenue per Share
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.01
-0.01
-0.02
-0.03
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
0.05
0.04
0.02
Tangible Book Value per Share
- -
- -
0.05
0.04
0.02
Basic Weighted Avg Shares
142
142
142
123
- -
Sales/Revenue/Turnover
1
- -
- -
- -
1
Operating Margin (%)
-303.71
-1,709.17
-1,756.95
-1,639.23
-1,276.81
Depreciation Expense
- -
- -
- -
- -
- -
Net Income, GAAP
-2
-2
-3
-4
-6
Effective Tax Rate (%)
- -
- -
- -
- -
- -
Profit Margin (%)
-303.97
-1,403.39
-1,682.86
-1,374.24
-1,091.87
Working Capital
- -
- -
7
5
3
LT Debt
- -
- -
- -
- -
- -
Total Equity
- -
- -
7
5
3
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-80.46
-59.2
-133.13

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-38.86%
Free Cash Flow
- -
- -
125.69%
Net Income, GAAP
- -
- -
49.24%
Sales/Revenue/Turnover
- -
- -
87.83%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
1

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.02
2025
- -
- -
- -
- -
-0.03
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Julian John Chick
Sector
Healthcare
Industry
Biotechnology
Address
157 Heidelberg Road Northcote VIC Australia 3070
IPO Date
Nov 25, 2024
Website
renerve.com.au
Similar Companies
Brii Biosciences Limited (BRIBF)
CK Life Sciences International (Holdings), Inc. (0775.HK)
More Life Company Corp. (MLCO.CN)
Leap Therapeutics, Inc. (LPTX)
BIONET Corp. (1784.TWO)
Zosano Pharma Corporation (ZSAN)
Business
ReNerve Limited, a medical device company, develops tissue-based products for peripheral nerve repair and replacement, and other related soft tissue surgical procedures in New Zealand and the United States. It develops Nerve Cuff, a bioabsorbable protective wrap used to protect repaired nerves; and Nerve Graft, an off-the-shelf nerve grafts for the repair of damaged nerves under the NervAlign brand. The company also offers dermal tissue product, a deep dermal product used in the repair of reconstructive and cosmetic surgical cases; and amniotic tissue product ranges used to aid the healing of wounds under the Empliq brand. In addition, it provides Nerve Conduit Range, a nerve conduit designed to facilitate nerve growth over short gaps between nerve ends; bionic nerve, a novel combination polymer technology; and Nerve Guide Matrix for treating more severe nerve injuries, but eliminating the need for patients to undergo additional sural nerve harvesting under the NervAlign brand that are in development phase. The company was incorporated in 2016 and is headquartered in Northcote, Australia.